Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Royalty Pharma plc incurred revolving credit of $1.8 billion with Bank of America, N.A., as Administrative Agent at base rate determined by reference to the highest of (1) the administrative agent maturing May 22, 2031.
- Instrument
- revolving credit
- Principal
- $1.8 billion
- Counterparty
- Bank of America, N.A., as Administrative Agent
- Rate
- base rate determined by reference to the highest of (1) the administrative agent
- Maturity
- May 22, 2031
- Event
- incurrence
Exact text from the filing
Credit Agreement were terminated in full. The Credit Agreement provides for an unsecured revolving credit facility (the “Revolving Credit Facility”) in an amount equal to $1.8 billion that is subject to an interest rate, at our option, of either (a) a base rate determined by reference to the highest of (1) the administrative agent’s prime rate, (2) the federal
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.99
Royalty Pharma plc entered into Revolving Credit Agreement with Bank of America, N.A., as Administrative Agent and the other lenders valued at $1,800,000,000 revolving credit facility, maturing May 22, 2031, with interest rate options based on (effective 2026-05-22).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- Bank of America, N.A., as Administrative Agent and the other lenders
- Value
- $1,800,000,000 revolving credit facility, maturing May 22, 2031, with interest rate options based on
- Effective
- 2026-05-22
Exact text from the filing
On May 22, 2026, Royalty Pharma plc (the “Company”), Royalty Pharma Holdings Ltd, a non-wholly owned consolidated subsidiary of the Company (“RPH”), and Royalty Pharma Manager, LLC (“RPM”) entered into that certain Revolving Credit Agreement with Bank of America, N.A., as Administrative Agent (the “Administrative Agent”) and the other lenders thereto (the “Credit Agreement”).
View on SEC.gov